Short answer
biote Corp. (BTMD) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $43M (down 9.6% year over year) with net income of $407,000.
Q3 2026 key financials · XBRL
- Revenue
- $43M
- −9.6% YoY · −2.0% QoQ
- Net income
- $407,000
- −95.0% YoY · +106.2% QoQ
- Operating margin
- 5.7%
- EPS (diluted)
- $0.01
- −95.5% YoY · +105.0% QoQ
Source: XBRL data from the biote Corp. (BTMD) Q3 2026 10-Q on SEC EDGAR. USD.
biote Corp. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $43.3M, down 9.6% YoY from $48.0M, driven by lower pellet procedures
- Net income $9.2M vs $4.2M net loss YoY, operating margin 5.7% vs 17.2%
- Best line: dietary supplements revenue up $0.8M; worst: pellet procedures down $5.1M, or 15.1%
- Cash $8.9M vs $24.1M at December 31, 2025; operating cash flow $6.4M vs $27.6M
- Recall, clinic attrition and covenant pressure: revolver reduced to $35.0M, additional liquidity actions under evaluation
Risk Factors
- New covenant risk: November 4, 2026 First Amendment waived noncompliance for the period ended September 30, 2026
- Financial risk: $125.0 million variable-rate Term Loan increases exposure to rising interest expense
- Liquidity risk: $35.0 million revolving facility and covenant breach could accelerate outstanding debt
- Strategic flexibility risk: Credit Agreement covenants may restrict expansion, business activities, and future financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other biote Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.